SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q1 FY22 results · Apr–Jun 2021
SMS Pharmaceuticals reported revenue from operations of ₹163.00 crore (up 44.4% from Q1 FY21) and net profit of ₹23.20 crore (up 230.1% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 163.00 | 112.90 | +44.4% | — | — |
| Other income | 1.29 | 0.81 | +58.5% | — | — |
| Total income | 164.29 | 113.71 | +44.5% | — | — |
| Profit before tax | 32.77 | 13.81 | +137.3% | — | — |
| Net profit for the period | 23.20 | 7.03 | +230.1% | — | — |
| EPS, basic (₹) | 2.74 | 0.83 | +230.1% | — | — |
| Net margin (%) | 14.2 | 6.2 | — |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 163.00 | 112.90 | +44.4% | 171.29 | −4.8% |
| Other income | 1.29 | 0.81 | +58.5% | 1.30 | −1.3% |
| Total income | 164.29 | 113.71 | +44.5% | 172.59 | −4.8% |
| Profit before tax | 32.77 | 13.81 | +137.3% | 34.31 | −4.5% |
| Net profit for the period | 23.20 | 9.20 | +152.1% | 23.14 | +0.3% |
| EPS, basic (₹) | 2.74 | 1.09 | +151.4% | 2.73 | +0.4% |
| Net margin (%) | 14.2 | 8.2 | 13.5 |
Consolidated
- Filed with BSE
- 07 Aug 2021, 16:49 IST
- Board meeting
- 07 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2021, 16:49 IST
- Board meeting
- 07 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE